The LDN Book
|Publisher||Chelsea Green Publishing|
|Media type||print & digital|
The LDN Book: How a Little-Known Generic Drug—Low Dose Naltrexone—Could Revolutionize Treatment for Autoimmune Diseases, Cancer, Autism, Depression, and More is a book by Linda Elsegood.
Publisher's synopsis[edit | edit source]
(This synopsis was provided by the publisher for promotional purposes. For book reviews, please see Links section below.)
Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity?
The LDN Book explains the drug's origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world's largest LDN charity organization with over 19,000 members worldwide. Featuring ten chapters contributed by medical professionals on LDN's efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.
Links[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
adverse reaction - Any unintended or unwanted response to the treatment under investigation in a clinical trial.